Table 4.
Group | Bone Marker | N | Baseline | 4 Month | P-value | |
---|---|---|---|---|---|---|
FES-T | CTX ng/mL | Group | 15 | 0.26 (0.15) | 0.24 (0.17) | 0.05* |
Male | 12 | 0.28 (0.15) | 0.31 (0.17) | 0.11** | ||
Female | 3 | 0.17 (0.17) | 0.22 (0.18) | 0.06** | ||
Osteocalcin µg/mL | Group | 15 | 16.70 (6.51) | 17.77 (6.23) | 0.02* | |
Male | 12 | 17.7 (6.80) | 18.87 (6.40) | 0.50** | ||
Female | 3 | 12.5 (3.04) | 13.40 (3.20) | 0.06** | ||
Sclerostin pmol/L | Group | 15 | 52.87 (16.78) | 54.34 (20.13) | 0.11** | |
Male | 12 | 53.27 (16.46) | 54.55 (20.93) | 0.24** | ||
Female | 3 | 51.30 (21.81) | 53.50 (20.66) | 0.06** | ||
CONV | CTX ng/mL | Group | 11 | 0.24 (0.21) | 0.27 (0.18) | 0.26** |
Male | 6 | 0.36 (0.23) | 0.35 (0.20) | 0.50** | ||
Female | 5 | 0.10 (0.02) | 0.16 (0.10) | 0.04** | ||
Osteocalcin µg/mL | Group | 11 | 20.10 (8.33) | 20.74 (8.62) | 0.28* | |
Male | 6 | 25.38 (7.53) | 25.36 (7.97) | 0.46** | ||
Female | 5 | 13.76 (3.25) | 15.20 (6.00) | 0.25** | ||
Sclerostin pmol/L | Group | 10 | 58.28 (12.43) | 61.06 (13.52) | 0.19* | |
Male | 6 | 63.60 (10.78) | 67.26 (15.04) | 0.17** | ||
Female | 5 | 52.96 (12.68) | 54.86 (9.46) | 0.25** |